The Covid-19 Disease in Pediatric Cancer Patients: A Single Center Experience
DOI:
https://doi.org/10.35916/thmr.v4i2.73Keywords:
Pediatric oncology, SARS-CoV-2, Covid-19, immunosuppressive, Chemotherapy.Abstract
Children with cancer can have a severe disease when infected with respiratory viruses. In this study, we aimed to understand the clinical course and outcomes of SARS-CoV-2 infection in children with cancer. Data evaluated about laboratory-confirmed SARS-CoV-2 infections in sixty-three children (<18 years) with cancer between 01.06.2020 - 01.08.2021 were retrospectively reviewed. Data for demographics, oncological diagnosis, clinical course, and cancer therapy details were collected. Primary outcomes were disease severity and modification to cancer-directed therapy. The median (range) age was 7.6 ± 5.3 (0-18) years, and the most common underlying diagnosis was leukemia (74.6%). The most common symptom was fever (67.7%), and most patients had symptoms (70%). The mild disease was most common (60.3%). During Covid-19 infection, disease severity increased 23 times (p=0.003) in those with fever and 4.083 (p=0.045) in those with neutropenia. It was observed that the severity of the disease increased 2.589 times as CRP increased (p<0.001). However, few patients (9.5%) were admitted to the intensive care unit. Five patients died, but none of the deaths could be attributed to Covid-19 alone. Most patients did not experience chemotherapy treatment interruption (57%). When interruption did occur, this duration was 13.9±14.3 (1.0-60.0) days. In this cohort of pediatric oncology patients, nearly 43% of patients who had Covid-19 were their chemotherapy interrupted. Future studies will only reveal the final effect of the pandemic on childhood cancer.
References
Coronavirus Update (Live) - Worldometer. www.worldometers.info. Accessed March 25, 2022.
Kebudi, R., Kurucu, N., Tu?cu. Covid-19 infection in children with cancer after the first wave in Turkey: A study of the Turkish pediatric oncology (TPOG) and hematology (TPHD) societies. Pediatric Blood & Cancer, 2021; 68: 139-140.
Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med, 2020; 382(17): 1663-1665.
Andre N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms? Pediatr Blood Cancer, 2020; 67(7): e28392.
Ashraf, U.M.; Abokor, A.A.; Edwards, J.M., et al. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol. Genom, 2021; 53(2):51-60.
Aleksova, A.; Ferro, F.; Gagno, G. et al. COVID-19 and renin-angiotensin system inhibition: Role of angiotensin-converting enzyme 2 (ACE2)-Is there any scientific evidence for controversy? J. Intern. Med, 2020, 288, 410–421.
Clerkin, K.J.; Fried, J.A.; Raikhelkar, J. et al. COVID-19 and Cardiovascular Disease. Circulation, 2020; 141, 1648–1655.
Paces, J.; Strizova, Z.; Smrz, D.; Cerny, J. COVID-19 and the immune system. Physiol. Res, 2020; 69, 379–388.
Abdulamir AS, Hafidh RR. The Possible Immunological Pathways for the Variable Immunopathogenesis of COVID—19 Infections among Healthy Adults, Elderly, and Children. Electron J Gen Med, 2020; 4(17): 1-4.
American Society of Hematology Research Collaborative (ASH RC). COVID-19 Registryin Hematology. ASH Research Collaborative. https://www.ashresearchcollaborative.org/s/covid-19-registry-datasummaries. It was accessed on 10 April 2022.
The Pediatric COVID-19 Cancer Case Report. 020.https://www.uab.edu/medicine/icos/icos-research/the-pocc-report. Accessed 12 April 2022.
Stokes CL, Patel PA, Sabnis HS, Mitchell SG, Yildirim IB, Pauly MG. Severe COVID-19 disease in two pediatric oncology patients. Pediatr Blood Cancer, 2020; 67(9): e28432.
Boulad F, Kamboj M, Bouvier N, Mauguen A, Kung AL. COVID-19 in children with cancer in New York City. JAMA Oncol, 2020; 6(9): 1459-1460
Gampel B, Troullioud Lucas AG, Broglie L, et al. COVID-19 disease in New York City pediatric hematology and oncology patients. Pediatr Blood Cancer, 2020; 67(9): e28420.
Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state. J Pediatric Infect Dis Soc, 2019; 8(1): 21-28.
Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics, 2020; published online 16 March.
WHO director-general’s statement on IHR Emergency Committee on Novel Coronavirus (2019- nCoV). https://www.who.int/covid-19. Accessed 03 March 2020.
Rojas T, Pérez-Martínez A, Cela E, et al. COVID-19 infection in children and adolescents with cancer in Madrid. Pediatr Blood Cancer, 2020; 67(7): e28397.
Bisogno G, Provenzi M, Zama D, et al. Clinical characteristics and outcome of severe acute respiratory syndrome coronavirus two infections in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. J Pediatric Infect Dis Soc, 2020; 9(5): 530-534.
Fauro A, Rives S, Laseletta A, et al. Initial reports on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-COV-2 pandemic. Pediatr Bood Cancer, 2020; 67(9): e28557.
Republic of Turkey Ministry of Health. COVID-19 Situation Reports in Turkey. ttp://covid19.saglik.gov.tr/Eklenti/37743/0/covid-19-situation-reportv4pdf. Accessed 30 June 2020.
GuanW-j, Ni Z-y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020; 382(18): 1708-1720.
Coronavirus Cancer Monitoring Project team. The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19. Lancet Oncol, 2020; 21(5):622-624.
Pallavi Madhusoodhan et all. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr Blood Cancer, 2021 Mar; 68(3): e28843.
Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr, 2020; 174(9): 868-873.
